Navigation Links
Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
Date:10/12/2008

Quark siRNAs Examined Alone and in Combination with Chemotherapy

FREMONT, Calif. Oct. 12 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that the journal Cancer Research published results on efficacy of siRNA targeting its proprietary target gene against non-small cell lung cancer (NSCLC) in the edition dated October 1, 2008. The paper, entitled "RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy," reports on research performed in collaboration with Professor Shyam Biswal of the Division of Pulmonary and Critical Care Medicine, School of Medicine, Johns Hopkins University. The results provide a basis for a potential new drug candidate to be added to Quark's pipeline.

The study examined efficacy of RNAi-mediated reduction of Nuclear Factor Erythroid-2-Related Factor 2 (Nrf2) expression in vitro and in in vivo mouse NSCLC xenograft models alone or in combination with chemotherapy. The results show that RNAi-mediated reduction of Nrf2 expression generates reactive oxygen species, suppresses tumor growth, and increases sensitivity to chemotherapeutic drug-induced cell death.

Elena Feinstein, M.D., Ph.D., Chief Scientific Officer of Quark Pharmaceuticals, said, "Nrf2 appears in our IP portfolio as a novel drug target for cancer treatment. Discovery of the target's role in cancer was made years ago, using our proprietary functional high throughput drug target discovery method, BiFAR(TM), when we looked for genes whose inhibition could sensitize cancer cells to apoptosis. Since then, much progress has been made to study the concept of Nrf2 inhibition for cancer treatment by the scientific community. One of the major contributors in this field is Prof. Biswal from Johns Hopkins University wi
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Va. , July 28, 2014  Serco ... services, announced the Company has been awarded a ... Support Command (NEMSCOM) and its Deployable Medical Systems.  ... enable medical personnel to provide world-class healthcare to ... operating environment across the globe. The five year ...
(Date:7/28/2014)... Ala. , July 28, 2014 ... J. Tipton , Ph.D., President and CEO of ... the Controlled Release Society (CRS) for the 2014-2015 ... annual meeting on July 12 in ... 40 countries.  The Controlled Release ...
(Date:7/28/2014)... Texas , July 28, 2014  MedSpring Urgent Care, an ... walk-in clinic at 517 S. Lamar Blvd., Austin, TX ... care clinic is located on the southeast corner of Barton ... on-site from 9 a.m. - 9 p.m. daily, including weekends and ... of Texas, Central Austin , Anderson Mill ...
Breaking Medicine Technology:Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3MedSpring Urgent Care opens Barton Springs walk-in clinic in Austin, TX 2
... May Offer Long-Lasting ... OLDSMAR, Fla., Aug. 25 Time. It is a precious,commodity. ... enough,of it. And the small amount of time a woman spends ... time she invests in others.,This reality has led many women in ...
... Front Line CLL, NHL and CLL Retreatment and Japanese Development Studies ... ... Genmab has,announced plans to begin four studies of ofatumumab in chronic ... to begin four studies of,ofatumumab in chronic lymphocytic leukemia (CLL) and follicular,non-Hodgkin,s ...
Cached Medicine Technology:Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
(Date:7/28/2014)... NJ (PRWEB) July 28, 2014 ... representing the majority of professionals engaged in the ... of the Transplantation and Immunology Research Network ... transplantation and immunology research. As modern organ transplantation ... a network that could provide more opportunities for ...
(Date:7/28/2014)... treatment for patients with one of the UK,s most ... , Chronic obstructive pulmonary disease (COPD) is the name ... due to long-term damage to the lungs. Often ... cent of all hospital admissions in the UK, with ... after they are discharged. , A team ...
(Date:7/28/2014)... 2014 With California in a record ... news that a fire blanket that is ... under development by SunSeeker Enterprises, Inc. The fire blanket—utilizing ... from the extreme heat of re-entry into the Earth's ... homes. , “Our firefighters routinely lay their very lives ...
(Date:7/28/2014)... Windsor, Co (PRWEB) July 28, 2014 ... Colorado has unveiled new plans to raise investment capital ... growing 24/7 fitness concept in the United States. , ... increasing popularity of 24/7 fitness centers provide a great ... into this rapidly expanding space. In addition to this, ...
Breaking Medicine News(10 mins):Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2
... CFO and Interim CEO of Everyday Wireless to ... A Place for Mom,( http://www.aplaceformom.com/ ) announced today ... of Finance. Longstreth will oversee,the financial performance of ... strategy, as well as evaluate new business,opportunities to ...
... 24 Karen Ignagni, President,and CEO of America,s ... in response to the U.S. House of Representatives,passage ... legislation that would require Medicare,Advantage beneficiaries to pay ... impact these cuts would have on vulnerable seniors.,As ...
... 24 LCA-Vision Inc. (Nasdaq:,LCAV), a leading provider ... announces the resignation of Executive Vice President,of Finance ... J.,Celebrezze has been named interim Chief Financial Officer, ... 2007, Mr. Celebrezze has served on the,Executive Management ...
... sicker patients may be getting bare metal devices, study ... patients who got drug-coated stents did better than those ... study found. , But it isn,t a simple either-or ... the experience of almost 39,000 Medicare recipients who underwent ...
... In lab setting, they caused some machines to turn ... (HealthDay News) -- Those magic little devices that allow ... toll electronically could interfere with the operation of critical ... laboratory setting not involving actual patients, Dutch scientists found ...
... agents could have unforeseen risks in individuals with heart ... in St. Louis. The anticancer drugs which go ... with a biochemical process that promotes growth in some ... this biochemical process in mice with heart disease led ...
Cached Medicine News:Health News:A Place for Mom, Nation's Largest Assisted Living and Senior Housing Referral Service Announces New Vice President of Finance 2Health News:AHIP Statement on House Passage of H.R. 6331 2Health News:LCA-Vision Announces CFO Change 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 2Health News:Drug-Coated Stents Reduce Repeat Artery Procedures 3Health News:Radio-Wave Devices May Play Havoc With Medical Equipment 2Health News:Radio-Wave Devices May Play Havoc With Medical Equipment 3Health News:Certain anti-cancer agents could be harmful to patients with heart disease 2Health News:Certain anti-cancer agents could be harmful to patients with heart disease 3
Inquire...
... (Low Melt), A low temperature agarose ... temperature , Optimal for in-gel restriction digestion/ligation ... a very manageable clear gel that provides ... at approximately 65°C and remains fluid at ...
... UltraClean Agarose, Molecular Biology ... electrophoretic separation of nucleic acids. ... isolate DNA fragments from 0.2 ... of UltraClean Agarose is tested ...
... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
Medicine Products: